Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
176 hedge funds and large institutions have $802M invested in Eagle Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 73 reducing their positions, and 17 closing their positions.
206% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $5.04M
7% more capital invested
Capital invested by funds: $751M → $802M (+$51.2M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
4% less funds holding
Funds holding: 183 → 176 (-7)
25% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WG
Winton Group
London,
United Kingdom
|
+$8.82M |
| 2 |
Renaissance Technologies
New York
|
+$7.18M |
| 3 |
BlackRock
New York
|
+$4.93M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$4.69M |
| 5 |
Goldman Sachs
New York
|
+$4.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HEC
Hudson Executive Capital
New York
|
-$8.85M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$5.51M |
| 3 |
MCM
Matarin Capital Management
New York
|
-$4.45M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.92M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.91M |
EGRX Hedge Fund Activity: Q4 2019 in Review
176 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2019, worth a combined $802M — up 6.8% from $751M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EGRX and 16 opened new positions — a net loss of 1 holder — while 73 trimmed existing stakes and 55 added.
The largest buyer was Winton Group, adding an estimated $8.82M. The largest seller was Hudson Executive Capital, cutting an estimated $8.85M.
- 176 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2019, down from 183 in Q3 2019.
- Funds reported $802M of Eagle Pharmaceuticals, Inc. stock for Q4 2019, up 6.8% quarter-over-quarter.
- 16 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2019 and 17 closed out, a net change of -1 holder.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2019 was Winton Group, an estimated $8.82M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2019 was Hudson Executive Capital, an estimated $8.85M sold.
Based on aggregated 13F filings for Q4 2019.